Anthem Blue Cross and Blue Shield Adds Coverage for Severe Emphysema Treatment
Retrieved on:
Thursday, September 30, 2021
Global, BCBS, Aetna, European Respiratory Journal, Policy, Blue Cross Blue Shield Association, Insurance, Laparoscopy, Solution, Randomized controlled trial, Multimedia, Patient, American Journal, Endoscopy, Critical Care Medicine (journal), Blue, General manager, Olympus, Chronic obstructive pulmonary disease, Respiratory disease, COPD, Freeman Health System, Safety, Anthem, American Journal of Respiratory and Critical Care Medicine, Quality of life, REACH, Medicine, Blue Cross, Olympus Corporation, DOI, Health insurance, Medical imaging, Medical device
CENTER VALLEY, Pa., Sept. 30, 2021 /PRNewswire/ --Olympus today announced that Anthem Blue Cross Blue Shield, the second largest commercial health plan in the country, has updated their coverage policy to include the Spiration Valve System for patients suffering from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease).
Key Points:
- CENTER VALLEY, Pa., Sept. 30, 2021 /PRNewswire/ --Olympus today announced that Anthem Blue Cross Blue Shield, the second largest commercial health plan in the country, has updated their coverage policy to include the Spiration Valve System for patients suffering from severe emphysema, a form of COPD (Chronic Obstructive Pulmonary Disease).
- "Olympus is very proud of its role in developing minimally invasive treatment options that provide an alternative to open surgery, which can further compromise patients who are already vulnerable with a chronic condition like emphysema."
- "Improving lung function in severe heterogenous emphysema with the Spiration Valve System (EMPROVE): a multicenter, open-label, randomized, controlled trial."
- The REACH study, a randomized controlled trial assessing the safety and effectiveness of the Spiration Valve System endobronchial therapy for severe emphysema: 12 month follow-up results.